Abu Dhabi DoH & French healthcare firm Sanofi join for clinical research projects

By Arya M Nair, Intern Reporter
  • Follow author on
DoH Image
Representational image

The Department of Health – Abu Dhabi (DoH), the regulator of healthcare in the emirate, has signed a Declaration of Collaboration (DoC) with Sanofi, a French multinational healthcare company.

The partnership reiterates Abu Dhabi’s ongoing efforts to position itself as a leading life science destination and an innovation hub. The DoC was signed by Dr. Asma Al Mannaei, Executive Director, Research and Innovation Centre at DoH and Mr. Jean-Paul Scheuer, MCO Lead & General Manager for Specialty Care at Sanofi in Greater Gulf.

The agreement will include the launch of a clinical research project and patient recruitment protocol. In relation to hematology and oncology, DoH and Sanofi agreed to pursue the creation of data generation and population research projects for late-stage breast cancer, liquid tumors and blood disorders.

Furthermore, both organizations will co-create a high-risk population screening project that will support the detection of rare metabolic diseases utilizing Artificial Intelligence (AI) tools.

Asma Al Mannaei
Asma Al Mannaei
Executive Director
Research Centre & Innovation
DoH

“Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as provide quality care and innovative treatments to patients. We are extremely delighted to have signed another agreement with a leading biopharmaceutical organization such as Sanofi.”

Additionally, the collaboration will witness the launch of the Supply Chain Academy, an initiative intended to provide and enhance knowledge related to the vaccine supply chain, which will be led by an International Federation of Purchasing and Supply Management (IFPSM) certified entity.

Mr. Scheuer said that “Our collaboration with DoH reflects our deep commitment to improving people’s lives, with our new-generation medicines, ongoing investments in research and support to healthcare providers across the region. We hope our partnership with DoH will address the urgent health issues facing the UAE and positively impact its healthcare sector. We look forward to sharing our expertise and working collaboratively to achieve shared goals, and serve patients, communities, and society at large.”

Related: Global Biopharma firm MSD GCC uplifts Abu Dhabi’s healthcare services with DoH


YOU MAY LIKE